Xenon Pharmaceuticals Inc.
XENEFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Xenon Pharmaceuticals Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Source: Xenon Pharmaceuticals Inc. — 10-K filed Feb 26, 2026
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 14 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 8, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Invesco Ltd. | 2026-03-31 | 59,103 | $3.44M | SEC filing |
| STEMPOINT CAPITAL LP | 2026-03-31 | 140,755 | $8.18M | SEC filing |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 2026-03-31 | 1,615,696 | $94M | SEC filing |
| TD Asset Management Inc | 2026-03-31 | 27,074 | $1.57M | SEC filing |
| Hudson Bay Capital Management LP | 2026-03-31 | 14,072 | $818K | SEC filing |
| CVA Family Office, LLC | 2026-03-31 | 33 | $1.92K | SEC filing |
| Erste Asset Management GmbH | 2026-03-31 | 50,000 | $2.78M | SEC filing |
| FIRST HORIZON CORP | 2026-03-31 | 24 | $1.4K | SEC filing |
| GAMMA Investing LLC | 2026-03-31 | 373 | $21.7K | SEC filing |
| MAI Capital Management | 2026-03-31 | 392 | $22.8K | SEC filing |
| Thrivent Financial for Lutherans | 2026-03-31 | 9,122 | Not shown | SEC filing |
| SBI Okasan Asset Management Co.Ltd. | 2026-03-31 | 14,400 | $800K | SEC filing |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2026-03-31 | 470,000 | $27.3M | SEC filing |
| Siren, L.L.C. | 2026-03-31 | 1,318,564 | $76.7M | SEC filing |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2026-03-31 | 1,342,028 | $78M | SEC filing |
| Vestal Point Capital, LP | 2026-03-31 | 639,900 | $37.2M | SEC filing |
| SANDERS MORRIS HARRIS LLC | 2026-03-31 | 21,500 | $1.25M | SEC filing |
| SEEDS INVESTOR LLC | 2026-03-31 | 3,423 | $203K | SEC filing |
| LETSON INVESTMENT MANAGEMENT, INC. | 2026-03-31 | 6,000 | $349K | SEC filing |
| SG Americas Securities, LLC | 2026-03-31 | 9,119 | Not shown | SEC filing |
- Each value is checked against Xenon Pharmaceuticals Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Xenon Pharmaceuticals Inc.'s share price.
120 filers have only one report here.
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-05 | PATOU GARY · Director | Common Shares | S — Open market or private sale | −1,322 | 53.14 | SEC filing |
| 2026-06-05 | Cannon Gillian · Director | Common Shares | S — Open market or private sale | −1,190 | 53.14 | SEC filing |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN · Chief Medical Officer | Common Shares | S — Open market or private sale | −1,410 | 55.23 | SEC filing |
| 2026-03-13 | DiFabio Andrea · Chief Legal Officer | Common Shares | S — Open market or private sale | −1,342 | 55.23 | SEC filing |
| 2026-03-13 | MORTIMER IAN · PRESIDENT & CEO | Common Shares | S — Open market or private sale | −7,308 | 55.23 | SEC filing |
| 2026-03-10 | DiFabio Andrea · Chief Legal Officer | Common Shares | S — Open market or private sale | −2,607 | 60.11 | SEC filing |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN · Chief Medical Officer | Common Shares | S — Open market or private sale | −2,771 | 60.11 | SEC filing |
| 2026-03-10 | MORTIMER IAN · PRESIDENT & CEO | Common Shares | S — Open market or private sale | −11,269 | 60.11 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-03 | Svoronos Dawn · Director | Share Option (Right to Buy) | A — Grant, award, or other acquisition | +10,507 | SEC filing |
| 2026-06-03 | Gover Justin D. · Director | Share Option (Right to Buy) | A — Grant, award, or other acquisition | +10,507 | SEC filing |
| 2026-06-03 | Svoronos Dawn · Director | Restricted Share Units | A — Grant, award, or other acquisition | +1,593 | SEC filing |
| 2026-06-03 | Cannon Gillian · Director | Share Option (Right to Buy) | A — Grant, award, or other acquisition | +10,507 | SEC filing |
| 2026-06-03 | GAROFALO ELIZABETH A. · Director | Restricted Share Units | A — Grant, award, or other acquisition | +1,593 | SEC filing |
| 2026-06-03 | Cannon Gillian · Director | Restricted Share Units | A — Grant, award, or other acquisition | +1,593 | SEC filing |
| 2026-06-03 | PATOU GARY · Director | Share Option (Right to Buy) | A — Grant, award, or other acquisition | +10,507 | SEC filing |
| 2026-06-03 | PATOU GARY · Director | Restricted Share Units | A — Grant, award, or other acquisition | +1,593 | SEC filing |
Showing 8 of 30 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-12-29 | ROBIN SHERRINGTON · EVP, Strategy & Innovation | Common Shares | J — Other acquisition or disposition | −8,398 | SEC filing |
Showing 1 of 1 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.